Tulane researcher shows enhanced therapeutic stem cell migration improves neurodegenerative disease – News from Tulane

Jean-Pyo Lee, PhD, assistant professor in the Department of Physiology at Tulane School of Medicine, in collaboration with colleagues at Sanford Burnham Prebys Medical Discovery Institute and the University of California San Diego, has shown for the first time that injection of a synthetic drug that attracts stem cell migration can improve neurological outcome in a mouse model of neurodegenerative disease. (Photo provided)

Stem cell therapy, especially neural stem cells, offers great promise in treating brain injury. Neural stem cells exhibit a broad repertoire of potentially multiple therapeutic actions including functional neural replacement and acute and chronic anti-inflammatory action via the delivery of therapeutic gene products synthesized inherently by the stem cells in the disease environment.

For optimal stem cell therapy, neural stem cells should migrate quickly and extensively to the site of injury and neurodegeneration.

Jean-Pyo Lee, PhD, assistant professor in the Department of Physiology at Tulane School of Medicine, in collaboration with colleagues at Sanford Burnham Prebys Medical Discovery Institute and the University of California San Diego, has shown for the first time that injection of a synthetic agonist (drug),that attracts stem cell migration can improve neurological outcome in a mouse model of neurodegenerative disease. The research was recently published by the Proceedings of the National Academy of Sciences of the United States of America and can be viewed here: https://www.pnas.org/content/early/2020/11/19/1911444117.

The study addresses the important nature of tropism of stem cell migration using neural stem cells, Lee said. Chemokines and chemokine receptors found inneural stem cells can mediate this activity.

In this study, human neural stem cells derived from induced pluripotent stem cells were used. Transplantation of human induced pluripotent stem cell-derived neural stem cells in a mouse model of a prototypical neurodegenerative disease improves neurological function and increases the life span of neurodegenerative mice.

The study also found that a synthetic chemokineanalog attracts these neural stem cellsand increases the beneficial impact of these stem cells on neurological disorders, Lee said. When this analog is co-administered with transplanted neural stem cells, the agonist (drug) enhanced stem cell migration, dissemination and integration into the diseased brains. Considering the prevalence of neurological diseases and current limitations of stem cell therapy, the findings will contribute to advancing the stem cell field and will be of great interest to further neurodegenerative disease research.

Excerpt from:
Tulane researcher shows enhanced therapeutic stem cell migration improves neurodegenerative disease - News from Tulane

Researchers restore lost sight in mice, offering clues to reversing aging – Science Magazine

Researchers reversed damage to the mouse eye (shown in a microscope image of a healthy animal, above) by genetically reprogramming neurons that make up the optic nerve.

By Kelly ServickDec. 2, 2020 , 5:30 PM

Do old and damaged cells remember what it was like to be young? Thats the suggestion of new study, in which scientists reprogrammed neurons in mouse eyes to make them more resistant to damage and able to regrow after injurylike the cells of younger mice. The study suggests that hallmarks of aging, and possibly the keys to reversing it, lie in the epigenome, the proteins and other compounds that decorate DNA and influence what genes are turned on or off.

The idea that aging cells hold a memory of their young epigenome is very provocative, says Maximina Yun, a regenerative biologist at the Dresden University of Technology who was not involved in the work. The new study supports that [idea], but by no means proves it, she adds. If researchers can replicate these results in other animals and explain their mechanism, she says, the work could lead to treatments in humans for age-related disease in the eye and beyond.

Epigenetic factors influence our metabolism, our susceptibility to various diseases, and even the way emotional trauma is passed through generations. Molecular biologist David Sinclair of Harvard Medical School, who has long been on the hunt for antiaging strategies, has also looked for signs of aging in the epigenome.

The big question was, is there a reset button? he says. Would cells know how to become younger and healthier?

In the new study, Sinclair and his collaborators aimed to rejuvenate cells by inserting genes that encode reprogramming factors,which regulate gene expressionthe reading of DNA to make proteins. The team chose three of the four factors scientists have used for more than 10 years to turn adult cells into induced pluripotent stem cells, which resemble the cells of an early embryo. (Exposing animals to all four factors can cause tumors.)

The team focused specifically on neurons at the back of the eye called retinal ganglion cells. These cells relay information from light-sensitive photoreceptors to the brain using long tendrillike structures called axons, which make up the optic nerve. Theres a stark divide between youth and age in these cells: An embryonic or newborn mouse can regenerate the optic nerve if it gets severed, but that ability vanishes with time.

To test whether their treatment could bring back some of that resilience, Sinclair and colleagues crushed the optic nerves of mice using forceps and injected a harmless virus into the eye carrying the genes for the three reprogramming factors. The injection prevented some damaged retinal ganglion cells from dying and even prompted some to grow new axons reaching back to the brain, the team reports today in Nature.

When the researchers looked at methylation patternsthe DNA location of chemical tags called methyl groups that regulate gene expressionthey found that changes caused by the injury resembled those in aging mouse cells. In certain parts of the genome, the treatment reversed those changes. The researchers also found that the benefits of the introduced genes depended on cells ability to alter their methylation patterns: Mice lacking certain enzymes necessary to remove methyl groups from DNA saw no benefit to the treatment.

Thats really something special, says Leonard Levin, a visual neuroscientist at McGill University. The experiments suggest how the famous and well-studied reprogramming factors restore cells. But big questions remain, he says: How do these factors cause methyl groups to be added or removed? How does that process help retinal ganglion cells?

Sinclairs team also tested the approach in mice with a condition meant to mimic glaucoma, a leading cause of age-related blindness in humans. In glaucoma, the optic nerve gets damaged, often by a buildup of pressure in the eye. Sinclair and his colleagues injected tiny beads into the animals eyes that prevented normal drainage and increased pressure, which damaged retinal ganglion cells.

Four weeks later, the animals visual acuity had declined by about 25%, as measured by a vision test in which mice move their heads to track the movement of vertical bars displayed on computer monitors. But after the genetic treatment, the animals gained back roughly half of their lost acuitythe first demonstration of restored vision in mice after this glaucomalike injury.

Still, the improvement in acuity was small, Levin notes. And, he says, the treated mice were in a relatively early stage of damage, not the state of near or total blindness that people experience when glaucoma goes untreated for years. So its too early to say whether this approach could benefit people who have lost much of their vision. Levin adds that there are already very good treatments for early-stage glaucoma to prevent vision loss with medicated eye drops or surgery to lower eye pressure.

In a final set of experiments, Sinclair and colleagues injected the reprogramming-factor genes into the eyes of 1-year-old healthy mice, roughly the mouse equivalent of middle-age. By this stage, the animals had visual acuity scores about 15% lower than their 5-month-old counterparts. Four weeks after treatment, older mice had similar acuity scores to younger ones. In their cells, the researchers saw patterns of DNA methylation and gene expression resembling those of younger animals.

In the three sets of experiments, Sinclair says, the cells seemed to respond to the reprogramming factors by fine-tuning their gene expression to match a youthful state. He sees that behavior as a hint that cells keep a record of their epigenetic past, even though its not clear how that record is stored. A company Sinclair cofounded, Life Biosciences, is developing treatments for diseases associated with aging, including glaucoma, and he says hes now planning to test the safety of this gene therapy approach in larger animals.

Yun says that as a strategy for reversing aging or treating disease, resetting the epigenome is a very difficult one. Reprogramming cells to an earlier state carries a risk of prompting uncontrolled growth and cancer.Future studies should test how the three factors affect other types of cells and tissues and confirm that reprogrammed cells maintain their youthful state long-term, she says. There are a lot of roads to be traveled.

Read more:
Researchers restore lost sight in mice, offering clues to reversing aging - Science Magazine

Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma | DNA RNA and Cells…

Details Category: DNA RNA and Cells Published on Monday, 07 December 2020 09:38 Hits: 377

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response

No Observed Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Host Disease

Six Doses of FT516 were Well-tolerated with No FT516-related Grade 3 or Greater Adverse Events Reported by Investigators

SAN DIEGO, CA, USA I December 04, 2020 I Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced positive interim data from the Companys dose escalation Phase 1 study of FT516 in combination with rituximab for patients with relapsed / refractory B-cell lymphoma. FT516 is the Companys universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells.

We are highly encouraged by these Phase 1 data, which clearly demonstrate that off-the-shelf, iPSC-derived NK cells can drive complete responses for cancer patients and that our proprietary hnCD16 Fc receptor can effectively synergize with and enhance the mechanism of action of tumor-targeted antibodies, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. Importantly, the safety profile of FT516 continues to suggest multiple doses of iPSC-derived NK cells can be administered in the outpatient setting, and supports potential use across multiple lines of therapy, including as part of early-line CD20-targeted monoclonal antibody regimens, for the treatment of B-cell lymphoma.

As of a November 16, 2020 data cutoff, three patients in the second dose cohort of 90 million cells per dose and one patient in the third dose cohort of 300 million cells per dose were available for assessment of safety and efficacy. All four patients were heavily pre-treated, having received at least two prior rituximab-containing regimens. Each patient received two 30-day treatment cycles, with each cycle consisting of fludarabine and cyclophosphamide lympho-conditioning followed by three once-weekly doses of FT516, IL-2 cytokine support, and rituximab.

Safety Data All four relapsed / refractory patients were administered FT516 in an outpatient setting with no requirement for inpatient monitoring. No dose-limiting toxicities, and no cases of any grade of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease, were observed. The multi-dose, two-cycle treatment regimen was well-tolerated with no FT516-related grade 3 or greater adverse events reported by investigators. In addition, no evidence of anti-product T- or B-cell mediated host-versus-product alloreactivity was detected, supporting the potential to safely administer up to six doses of FT516 in the outpatient setting without patient matching. All grade 3 or greater treatment emergent adverse events were not related to FT516 and were consistent with lympho-conditioning chemotherapy and underlying disease.

Activity Data Three of four relapsed / refractory patients achieved an objective response, including two complete responses (CR), following the second FT516 treatment cycle as assessed by PET-CT scan per Lugano 2014 criteria. A CR was achieved in one patient with diffuse large B-cell lymphoma (DLBCL) who was most recently refractory to a rituximab-containing treatment regimen, and a CR was achieved in one patient with follicular lymphoma (FL) who had previously been treated with four rituximab-containing treatment regimens. Notably, in one patient for which an interim tumor assessment showed a partial response following the first FT516 treatment cycle, the response deepened to a CR following administration of the second FT516 treatment cycle, suggesting that additional FT516 treatment cycles can confer clinical benefit.

M = million; CR = Complete Response; PR = Partial Response; PD = Progressive Disease As of November 16, 2020 database entry. Data subject to cleaning and source document verification. 1 Day 29 of the second FT516 treatment cycle as assessed per Lugano 2014 criteria

Dose escalation is continuing in the current dose cohort of 300 million cells per dose in combination with rituximab, and a fourth dose cohort of 900 million cells per dose in combination with rituximab is planned. The Company previously reported that two patients treated in the first dose cohort of 30 million cells per dose in combination with rituximab showed a protocol-defined response assessment of progressive disease. No events of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease were observed in either patient.

About Fate Therapeutics iPSC Product Platform The Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About FT516 FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies. CD16 mediates antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. ADCC is dependent on NK cells maintaining stable and effective expression of CD16, which has been shown to undergo considerable down-regulation in cancer patients. In addition, CD16 occurs in two variants, 158V or 158F, that elicit high or low binding affinity, respectively, to the Fc domain of IgG1 antibodies. Scientists from the Company have shown in a peer-reviewed publication (Blood. 2020;135(6):399-410) that hnCD16 iPSC-derived NK cells, compared to peripheral blood NK cells, elicit a more durable anti-tumor response and extend survival in combination with anti-CD20 monoclonal antibodies in an in vivo xenograft mouse model of human lymphoma. Numerous clinical studies with FDA-approved tumor-targeting antibodies, including rituximab, trastuzumab and cetuximab, have demonstrated that patients homozygous for the 158V variant, which is present in only about 15% of patients, have improved clinical outcomes. FT516 is being investigated in an open-label, multi-dose Phase 1 clinical trial as a monotherapy for the treatment of acute myeloid leukemia and in combination with CD20-targeted monoclonal antibodies for the treatment of advanced B-cell lymphoma (NCT04023071). Additionally, FT516 is being investigated in an open-label, multi-dose Phase 1 clinical trial in combination with avelumab for the treatment of advanced solid tumor resistant to anti-PDL1 checkpoint inhibitor therapy (NCT04551885).

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

SOURCE: Fate Therapeutics

Read the original here:
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma | DNA RNA and Cells...

Bayer and Atara Biotherapeutics in CAR T-cell therapy deal – BioPharma-Reporter.com

Atara is a pioneer in allogeneic T-cell immunotherapy with industry-leading allogeneic cell manufacturing processes and CAR T technologies.

Under the terms of the deal, that San Francisco-based innovator will receive an upfront payment of US60m, and up to a total of US$610m for development, regulatory and commercialization milestones, plus tiered royalties up to low double-digit percentage of net sales.

The collaboration will focus on Ataras off-the-shelf allogeneic T-cell immunotherapy, ATA3271, for high mesothelin-expressing tumors, and its autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.Both therapies were developed in conjunction with Memorial Sloan Kettering Cancer Center (MSK).

Mesothelin is a tumor-specific antigen that is commonly expressed at high levels on the cell surface in many aggressive solid tumors and is an attractive target for immune-based therapies, including CAR T therapy.

Both ATA2271 and ATA3271 are engineered for use in solid tumors as they incorporate Ataras novel inclusion of both a PD-1 DNR construct to overcome checkpoint inhibition and a 1XX costimulatory domain on the CAR (chimeric antigen receptor) to enhance expansion and functional persistence of the CAR T cells.

ATA3271, the allogeneic version of this CAR T, leverages Ataras EBV T-cell platform and is currently in IND-enabling studies. ATA2271, the autologous version, has enrolled the first patient in an open-label, single-arm Phase 1 clinical study in November 2020.

Bayer said the deal is a fundamental element of its new cell and gene therapy strategy. It strengthens our development portfolio through allogeneic cell therapies and consolidates our emerging leadership in the field, said Wolfram Carius, head of the pharma giants CGT unit.

We look forward to collaborating with Atara to develop off-the-shelf CAR T-cell therapies for patients with difficult-to-treat cancers, he added.

Pascal Touchon, CEO of Atara, said Bayers proven track record in oncology global development and commercialization, and growing presence in cell and gene therapy, enhances Ataras capabilities and complements its leading allogeneic T-cell platform.

Atara is to lead the Investigational New Drug (IND)-enabling studies and process development for ATA3271 while Bayer will be responsible for submitting the IND and subsequent clinical development and commercialization. Atara will also continue to be responsible for the ongoing ATA2271 phase 1 study, for which an IND filing has been accepted and the clinical trial initiated.

As part of the deal, Atara will also provide translational and clinical manufacturing services to be reimbursed by Bayer. In addition, for a limited period of time, Bayer has a non-exclusive right to negotiate a license for additional Atara CAR T product candidates.

In order to build up its presence in the CGT sphere, Bayer said it is focused on strengthening its internal capabilities in that respect.

In parallel, it says it is pursuing external strategic collaborations, technology acquisitions and licensing. The goal is to build robust platforms with broad application across different therapeutic areas.

It outlined selected areas of CGT for its strategic focus including stem cell therapies with an emphasis on induced pluripotent cells or iPSCs - gene augmentation, gene editing and allogeneic cell therapies in different indications.

Leveraging external innovation together with the expertise of the teams at Bayer represents a key value-driver, especially in the highly dynamic and competitive field of CGT. Bayers operating model for CGT, where partners operate autonomously and are fully accountable to develop and progress their portfolio and technology, is essential for preserving their entrepreneurial culture and positions Bayer as a partner of choice.

Visit link:
Bayer and Atara Biotherapeutics in CAR T-cell therapy deal - BioPharma-Reporter.com

Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price – Being Patient

Groundbreaking research in stem cells has propelled scientists understanding of neurodegenerative diseases, including Parksinsons. Could stem cell therapies one day help cure Alzheimers?

Clinical trials of stem cell therapies are now underway to repair the damaged cells of people with Parkinsons disease and age-related macular degeneration. Being Patient spoke with Jack Price, professor of developmental neurobiology at Kings College London and author of the book The Future of Brain Repair, about the potential and challenges of repairing the brain with stem cell therapy.

Being Patient: What is stem cell therapy?

Prof. Jack Price: Its the transplantation of stem cells, either directly into the brain or in a way that gives them access to the brain and influence the brain, to bring about a therapeutic effect.

Being Patient: Are there stem cells in the brain?

Prof. Jack Price: For many years, neuroscientists didnt think there were stem cells in the brain. We now know there are. We know about a population [of stem cells] thats become very important in our understanding of Alzheimers disease and in mood disorders like anxiety and depression. These are stem cells that are found in a part of the brain called the hippocampus.

But by and large, the brain doesnt have stem cells, unlike skin and other tissues in the body. The blood is the classic [example]: Theres a population of stem cells in the bone marrow that regenerates blood all the time.

Being Patient: What makes stem cells so special and why are they a focus of research?

Prof. Jack Price: The definition of stem cells is a population of cells that gives rise to other types of cells. In neural stem cells, precursor cells can make adult brain cells, nerve cells, glial cells, all the different cell types that make up the brain. If you have a disease like Alzheimers or any other neurodegenerative disease, where we know the key pathology is the loss of nerve cells, your brain doesnt normally have the ability to replace those lost brain cells. The idea was [that] if you put stem cells where the loss of brain cells has taken place, maybe those stem cells would replace the lost cells.

Being Patient: What is the potential of stem cell therapy in treating neurodegenerative diseases?

Prof. Jack Price: Theres a piece of absolutely brilliant stem cell science that was done by Shinya Yamanaka in Kyoto in 2006. He showed you could effectively take any cell through a very straightforward genetic manipulation that he discovered, [and] turn them into what we call pluripotent stem cells, which are cells that can make any cell type in the body. They also have an ability that other stem cells generally dont: They can build tissue. If you grow them in a little culture dish, they can start to make little pieces of brain called organoids or cerebroids. This was a groundbreaking technology.

In Parkinsons disease, theres enormous progress and clinical trials are underway now. We know more about the pathology of Parkinsons disease [than in Alzheimers]. The pathology of Alzheimers turns out to be quite complex, and weve had, over the years, quite a few ideas about how it worked. But [turning] those into actual therapies hasnt quite worked as we expected, and we keep having to go back and rethink whats going on in Alzheimers.

The pathology of Parkinsons disease is also difficult. Its not trivial. But at the same time, one thing is clear: a lot of the pathology is associated with the loss of a particular population of nerve cells the midbrain dopaminergic cells. We can start with these pluripotent stem cells and make them make precisely the right type of dopaminergic cell that we know is lost in Parkinsons disease.

This is built on 30 [to] 40 years of research of people trying to find exactly the right cell type to work [with] in Parkinsons disease. They had some early success and fell backwards. But this technology looks much more precise than everything anybodys ever tried before.

In age-related macular degeneration, the disease of the eye where you lose your retinal photoreceptors, there are very clever strategies now where people are using these pluripotent stem cells to make a thing called a retinal pigment epithelium. It lies behind the retina, but its what supports the photoreceptors. It turns out, thats what goes wrong in age-related macular degeneration.

Being Patient: Are there any stem cell therapy approved to treat brain disorders?

Prof. Jack Price: There are no licensed stem cell therapy for any brain disorders anywhere in the world for the simple reason [that] nobody has shown one works. There are a lot of stem cell clinics in the U.S. and somewhat fewer elsewhere who are offering cell therapies that are untested. Theyll put stem cells into you for any disorder youve got. Those cell therapies do not work.

A lot of genuine companies are trying to get these cell therapies to work in clinical trials and falling flat on their face quite often, despite their best efforts. 90% of clinical trials fail, and thats clinical trials of conventional drugs by drug companies that know what theyre doing.

What do you suppose is the chance with a stem cell therapy [that] we dont really understand how it works, [that] we dont quite know how to manufacture it properly, [and that] we dont quite know what cells we really want, of working? The chance is almost zero. These companies know that, which is why theyre not going to clinical trials.

The interview has been edited for length and clarity.

Contact Nicholas Chan at nicholas@beingpatient.com

Link:
Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price - Being Patient

Global Induced Pluripotent Stem Cells Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by…

Global Induced Pluripotent Stem Cells Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

The Lexis Business Insights added a new report Global Induced Pluripotent Stem Cells Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 2024 in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting.

In 2020, the global Induced Pluripotent Stem Cells Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2025.

The global Induced Pluripotent Stem Cells Market report offers a complete overview of the Induced Pluripotent Stem Cells Market globally. It presents real data and statistics on the inclinations and improvements in global Induced Pluripotent Stem Cells Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Induced Pluripotent Stem Cells Market report elaborates the crucial data along with all important insights related to the current market status.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Induced Pluripotent Stem Cells market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-184748

Top key players @ Fujifilm Holding Corporation, Astellas Pharma, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Celgene Corporation, Aastrom Biosciences, Acelity Holdings, StemCells, Japan Tissue Engineering, Organogenesis, and

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Induced Pluripotent Stem Cells market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Induced Pluripotent Stem Cells Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Induced Pluripotent Stem Cells Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Induced Pluripotent Stem Cells Market?

What are the key market trends impacting the growth of the Global Induced Pluripotent Stem Cells Market?

What are the challenges to market growth?

Who are the key vendors in the Global Induced Pluripotent Stem Cells Market?

What are the market opportunities and threats faced by the vendors in the Global Induced Pluripotent Stem Cells Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Induced Pluripotent Stem Cells Market;

3.) The North American Induced Pluripotent Stem Cells Market;

4.) The European Induced Pluripotent Stem Cells Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

Market Dynamics

The report analyzes the factors impacting the growth and the current market trends influencing the global Induced Pluripotent Stem Cells market. Detailed pricing information with ex-factory prices of various products by key manufacturers form a crucial part of the report. Competition analysis, along with regional government policies affecting the Induced Pluripotent Stem Cells market provides a detailed overview of the current status and prospects of the market. The impact of the ever-growing global population, coupled with technological advancements affecting the global Induced Pluripotent Stem Cells market is also covered in the report.

Drivers & Constraints

The report provides extensive information about the factors driving the global Induced Pluripotent Stem Cells market. Factors influencing the growth of the Induced Pluripotent Stem Cells market, along with technological advancements, are discussed extensively in the report. The current restraints of the market, limiting the growth and their future impact are also analyzed in the report. The report also discusses the impact of rising consumer demand, along with global economic growth on the Induced Pluripotent Stem Cells market.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.lexisbusinessinsights.com/request-sample-184748

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Statistical surveying reports are a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Read the original:
Global Induced Pluripotent Stem Cells Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by...

Industry Verticals: Induced Pluripotent Stem Cells (iPSC) Market Latest and updated Scope and Application 2020-2027 – The Blend

The global induced pluripotent stem cells (ipsc) market is estimated to surpass $2,638.5 million by 2027, exhibiting a CAGR of 7.8% from 2020 to 2027.

The report aims to offer a clear picture of the current scenario and future growth of the global Induced Pluripotent Stem Cells (iPSC) market. The report provides scrupulous analysis of global market by thoroughly reviewing several factors of the market such as vital segments, regional market condition, market dynamics, investment suitability, and key players operating in the market. Besides, the report delivers sharp insights into present and forthcoming trends & developments in the global market.

The report articulates the key opportunities and factors propelling the global Induced Pluripotent Stem Cells (iPSC) market growth. Also, threats and limitations that have the possibility to hamper the market growth are outlined in the report. Further, Porters five forces analysis that explains the bargaining power of suppliers and consumers, competitive landscape, and development of substitutes in the market is also sketched in the report.

For More Detail Insights, Download Sample Copy of the Report at:https://www.researchdive.com/download-sample/759

The report reveals various statistics such as predicted market size and forecast by analyzing the major factors and by assessing each segment of the global Induced Pluripotent Stem Cells (iPSC) market. Regional market analysis of these segments is also provided in the report. The report segments the global market into four main regions including Asia-Pacific, Europe, North America, and LAMEA. Moreover, these regions are sub-divided to offer an exhaustive landscape of the Induced Pluripotent Stem Cells (iPSC) market across key countries in respective regions. Furthermore, the report divulges some of the latest advances, trends, and upcoming opportunities in every region.

Furthermore, the report profiles top players active in the global Induced Pluripotent Stem Cells (iPSC) market. A comprehensive summary of 10 foremost players operating in the global market is delivered in the report to comprehend their position and footmark in the industry. The report highlights various data points such as short summary of the company, companys financial status and proceeds, chief company executives, key business strategies executed by company, initiatives undertaken & advanced developments by the company to thrust their position and grasp a significant position in the market.

RESEARCH METHODOLOGY

The research report is formed by collating different statistics and information concerning the Induced Pluripotent Stem Cells (iPSC) market. Long hours of deliberations and interviews have been performed with a group of investors and stakeholders, including upstream and downstream members. Primary research is the main part of the research efforts; however, it is reasonably supported by all-encompassing secondary research. Numerous product type literatures, company annual reports, market publications, and other such relevant documents of the leading market players have been studied, for better & broader understanding of market penetration. Furthermore, medical journals, trustworthy industry newsletters, government websites, and trade associations publications have also been evaluated for extracting vital industry insights.

Connect with Our Analyst to Contextualize Our Insights for Your Business:https://www.researchdive.com/connect-to-analyst/759

KEY MARKET BENEFITS

KEY MARKET SEGMENTS

The global Induced Pluripotent Stem Cells (iPSC) market is segmented on the basis of the following:

Global Induced Pluripotent Stem Cells (iPSC) Market By Product Type:

Global Induced Pluripotent Stem Cells (iPSC) Market By Applications:

Global Induced Pluripotent Stem Cells (iPSC) Market By Regions:

Top Leading key players stated in Global Induced Pluripotent Stem Cells (iPSC) Market report are:

Axol Bioscience Ltd., Cell Applications, Inc, Cellular Dynamics, Inc., Cynata Therapeutics, Fate Therapeutics, Ncardia, Reprocell, Thermo Fisher Scientific, Takara Bio, Inc.

The report also summarizes other important aspects including financial performance, product portfolio, SWOT analysis, and recent strategic moves and developments of the leading players.

Contact Us:

Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) + 91 (788) 802-9103 (India) +1 (917) 444-1262 (US) Toll Free : +1 -888-961-4454 Email:support@researchdive.com LinkedIn:https://www.linkedin.com/company/research-dive Twitter:https://twitter.com/ResearchDive Facebook:https://www.facebook.com/Research-Dive Blog:https://www.researchdive.com/blog Follow us on:https://covid-19-market-insights.blogspot.com

Read more:
Industry Verticals: Induced Pluripotent Stem Cells (iPSC) Market Latest and updated Scope and Application 2020-2027 - The Blend

Bayer Launches Cell and Gene Therapy Platform to Maximize Recent Acquisitions – PharmaLive

Less than two months after life sciences giant Bayer acquired N.C.-based AskBio, a gene therapy company, the healthcare giant launched a cell and gene therapy platform within its pharmaceutical division.

This morning, Bayer said the launch of the new platform is a deeply transformative move for its business. Stefan Oelrich, a member of Bayers Board of Management and president of the companys Pharmaceuticals Division, pointed to the impact cell and gene therapies have made in treating diseases and said the companys goal is to be at the forefront of this revolution in science. The company tapped Wolfram Carius, its current vice president of Pharmaceuticals Product Supply, to head the new program.

The C> field is growing at an unprecedented pace. With the establishment of Bayers own C> Platform our company will propel its presence in this area. This will complement our existing C> pipeline which already includes five advanced assets with at least three investigational new drugs annually for the next years, Oelrich said in a statement.

To boost its cell and gene therapy presence, Bayer said it is strengthening its internal capabilities and will also pursue external strategic collaborations, technology acquisitions and licensing. In October, the company acquired AskBios AAV-based gene therapy pipeline of treatments and its Pro10 AAV manufacturing process, which has become something of a standard across the industry. The Pro10 AAV process is used by multiple companies, including Pfizer, Takeda and Viralgen Vector Core SA.Bayer now owns AskBios pipeline of treatments for Pompe disease, Parkinsons disease, as well as therapies for neuromuscular, central nervous system, cardiovascular and metabolic diseases.

The addition of AskBio complements Bayers other cell and gene therapy company, BlueRock Therapeutics, which itacquired last year. BlueRock is developing induced pluripotent stem cells (iPSC), with its most advanced program aimed at Parkinsons disease. In addition to the two companies, Bayer also acquired a contract manufacturing organization that specializes in gene therapy. Bayer said it has established a C> pipeline that includes five advanced assets and more than fifteen preclinical candidates.

The new C> Platform will combine multiple functions by providing support across the entire value chain for the research and development of cell and gene therapies, the company said. This includes support in preclinical development, CMC, clinical programs, project management and more. The platform will guide projects form concept through commercial launch. The goal is to build robust platforms with broad application across different therapeutic areas, the company said.

The emerging bio revolution represents a once-in-a-lifetime opportunity and a new era for Bayer, said Carius said in a statement. A dedicated C> Platform is vital to accelerate innovation at its source, and to ensure its translation into tangible therapies for patients who have no time to wait.

The C> Platform will allow its partners to operate autonomously to develop and progress their portfolio and technology. The role of Bayers C> Platform is to serve as a strategic guide to ensure the different parts of the organization complement each other and combine the best in Biotech and Pharma know-how.

nitpicker/Shutterstock

The formation of the C> Platform comes one day after Bayer and Blackford Analysis entered into a development and license agreement to establish an artificial intelligence (AI) platform for medical imaging. The platform will enable the integration of AI applications into the medical imaging workflow which can support the complex decision-making process of radiologists and is intended to enhance diagnostic confidence, the companies said.

Also this week, Bayer sold most of its stake in Elanco Animal Health for $1.6 billion to cover legal bills from ongoing litigation over the weedkiller Roundup and its alleged role as a carcinogen. Bayer owned approximately 15.5% of Elanco, but faces nearly $11 billion in potential damages related to Roundup lawsuits. In June, the company proposed a $12 billion agreement to resolve Roundup litigation.

Last week, a federal judge rejected a $650 million settlement claim for pollution related to polychlorinated biphenyl, or PCB, which is used to cool heavy-duty electrical equipment.

Go here to read the rest:
Bayer Launches Cell and Gene Therapy Platform to Maximize Recent Acquisitions - PharmaLive

Stem Cells Market Size on Target to Reach US$ 17.79 Billion 2027 – Cheshire Media

The Global Stem Cells Market size is projected to reach US$ 17.79 Billion by 2027, registering a CAGR of 8.61% during the forecast period 2020 to 2027.The market report provides an analysis of the global Stem Cells Market for the period 2016-2027, wherein 2020 to 2027 is the forecast period and 2019 is considered as the base year.

COVID-19 pandemic has impacted all over industries across the globe, and Stem Cells Market is one of them. As the global market heads towards major recession, we are at Precedence Research, has published a brand-new latest research report which fully studies the impact of COVID-19 crisis on Stem Cells Industry and suggests possible actions to curtail them. This market report covers an in-depth analysis of the Stem Cells industry including statistical, quantitative, qualitative data points with emphasis on the market dynamics including the growth factors, drivers, opportunities & restraints, market size, share, industry status and forecast, competition landscape and growth and revenue opportunities after COVID-19 pandemic.

The Final Report will cover the impact analysis of COVID-19, Get a FREE SAMPLE PDF (Including Full TOC, Table & Figures) @https://www.precedenceresearch.com/sample/1118

The report gives correct insights on the current market scenario and future prospects of theStem Cellsindustry. It expertly describes historic data, present market trends, market environment, technological improvements, upcoming technologies and the technical progress in the related industry. Top market leaders, major collaborations, mergers & acquisitions are reviewed comprehensively in theStem Cellsmarket report.

Moreover, this market study also analyses the market status, market share, growth rate (CAGR), future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis. Market risks and entry barriers makes the Stem Cells industry attentive and help to decide further moves.

Stem Cells Market 2020 to 2027 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

Get Customization on this Research [emailprotected]https://www.precedenceresearch.com/customization/1118

Market Segmentation as below:

Segments Covered in the Report

This research study comprises complete assessment of the market by means of far-reaching qualitative and quantitative perceptions, and predictions regarding the market. This report delivers classification of marketplace into impending and niche sectors. Further, this research study calculates market size and its development drift at global, regional, and country from 2016 to 2027. This report contains market breakdown and its revenue estimation by classifying it on the basis of product, application, technology, therapy and region as follows:

By Product

By Application

By Technology

By Therapy

Market By Geography (Regional Output, Demand & Forecast by Countries)

Along with these, for proper market understanding, the major aspects like economic, social, political, and environmental, along with the major regulations and standards in accordance with the Stem Cells Market are covered. For the same, Porters five forces model, value chain analysis, cost structure analysis, and player positioning analysis are covered.

The 2020 Annual Stem Cells Market Offers:

100 + charts exploring and analyzing the Stem Cells Market from critical angles including retail forecasts, consumers demand, production, and more

10 + profiles of topStem CellsMarket producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Highlights of the Report:

The research provides answers to the following key questions:

The Final Report will cover the impact analysis of COVID-19.

Buy Your Exclusive PDF Copy Now @ https://www.precedenceresearch.com/checkout/1118

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call:+1 774 402 6168

Email:[emailprotected]

Follow us on LinkedIn

More here:
Stem Cells Market Size on Target to Reach US$ 17.79 Billion 2027 - Cheshire Media

Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation | More News | News Channels – PipelineReview.com

Details Category: More News Published on Thursday, 03 December 2020 11:22 Hits: 540

BERLIN, Germany I December 2, 2020 I Bayer AG announced today the launch of a Cell and Gene Therapy (C>) Platform within its Pharmaceuticals division. Through this strategic platform, the company further consolidates its emerging leadership in the field and takes a deeply transformative step for its business.

This is a defining moment for Bayer. Cell and gene therapies are leading innovation in healthcare, and it is our goal to be at the forefront of this revolution in science, said Stefan Oelrich, Member of the Board of Management, Bayer AG and President Pharmaceuticals Division. The C> field is growing at an unprecedented pace. With the establishment of Bayers own C> Platform our company will propel its presence in this area. This will complement our existing C> pipeline which already includes five advanced assets with at least three investigational new drugs annually for the next years.

In order to build up its presence in C>, Bayer is strengthening its internal C> capabilities. At the same time, the company is pursuing external strategic collaborations, technology acquisitions and licensing. The goal is to build robust platforms with broad application across different therapeutic areas. For example, Bayer has just acquired an industry-leading contract manufacturing organization in gene therapy. Together with Bayers expertise and recent investments in product supply capabilities, this will contribute to fill an important global demand gap for development and manufacturing of gene therapies.

Strategically, Bayer focuses on selected areas of C>, such as stem cell therapies (with focus on induced pluripotent cells or iPSCs), gene augmentation, gene editing and allogeneic cell therapies in different indications. With the acquisition of BlueRock Therapeutics in 2019 and the recent acquisition of Asklepios Biopharmaceutical, successfully closed on December 1, 2020, the first partners are integrating into Bayers C> Platform. Furthermore, the company has secured industry-leading expertise in the areas of gene augmentation and regenerative cell therapies. Bayer has also established a vibrant C> pipeline comprising five advanced assets and over fifteen preclinical candidates.

Leveraging external innovation together with the expertise of the teams at Bayer represents a key value-driver, especially in the highly dynamic and competitive field of C>. Bayers operating model for C>, where partners operate autonomously and are fully accountable to develop and progress their portfolio and technology, is essential for preserving their entrepreneurial culture and positions Bayer as a partner of choice. The role of Bayers C> Platform is to steer strategically, ensuring the different parts of the organization complement each other and combining the best in Biotech and Pharma know-how.

The emerging bio revolution represents a once-in-a-lifetime opportunity and a new era for Bayer, said Wolfram Carius, Head of Bayers new C> Platform. A dedicated C> Platform is vital to accelerate innovation at its source, and to ensure its translation into tangible therapies for patients who have no time to wait.

As part of the Pharmaceuticals Division, the C> Platform will combine multiple backbone functions providing support across the entire value chain for the research and development of cell and gene therapies. This includes expertise in Research and Preclinical Development, CMC (Chemistry, Manufacturing and Controls), Clinical Development, Commercial, Strategy Implementation and Project Management. With a high level of flexibility, it will orchestrate operations from science to launch in order to generate and maintain a sustainable pipeline, with the goal to bring breakthrough science to market as fast as possible.

About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to http://www.bayer.com.

SOURCE: Bayer

Read the original post:
Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation | More News | News Channels - PipelineReview.com